Funobactam
Jump to navigation
Jump to search
| Clinical data | |
|---|---|
| Other names | XNW-4107 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C13H17N7O6S |
| Molar mass | 399.38 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Funobactam is an investigational new drug that is being evaluated for the treatment of hospital-acquired bacterial pneumonia.[1] It is a β-lactamase inhibitor.[2]
References
[edit | edit source]- ^ Clinical trial number NCT05204563 for "Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2) (REITAB-2)" at ClinicalTrials.gov
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).